Piramal Pharma Solutions has enhanced its capabilities with the addition of the Korsch XM-12 bilayer tablet press at its Morpeth facility. This strategic investment reinforces the company’s commitment to advancing drug delivery, quality, and patient-centricity. The XM-12 is designed for both single-layer and bilayer production, featuring advanced sanitary fittings, a special product chute for high potency APIs, and rapid changeover turrets. The press enables the facility to produce premium tablets at scale with accuracy, speed, and flexibility.
To ensure the safe and efficient operation of the XM-12, Piramal Pharma Solutions has implemented comprehensive training protocols for its scientists, operators, and maintenance teams. The training will be tailored to meet the unique requirements of each role within the Formulation Development Team, covering both bilayer and single-layer modes, changeovers, cleaning, and containment testing. The XM-12 is equipped with built-in technology that maintains consistent precision output with minimal operator interaction once critical settings are established.
The addition of the Korsch XM-12 is a significant milestone for Piramal Pharma Solutions, demonstrating its commitment to delivering innovative therapies to patients worldwide. As a Contract Development and Manufacturing Organization (CDMO), Piramal Pharma Solutions offers end-to-end development and manufacturing solutions across the drug life cycle, serving customers through a globally integrated network of facilities in North America, Europe, and Asia.
Piramal Pharma Solutions is part of Piramal Pharma Limited, a company that offers a portfolio of differentiated products and services through its global development and manufacturing facilities and distribution network. Piramal Pharma Limited includes Piramal Pharma Solutions, Piramal Critical Care, and Piramal Consumer Healthcare, among other businesses. The company has a strategic minority investment in Yapan Bio Private Limited, which operates in the biologics and bio-therapeutics segments.
The Korsch XM-12 bilayer tablet press is a key addition to Piramal Pharma Solutions’ capabilities, enabling the company to produce high-quality tablets with precision and efficiency. With its advanced features and comprehensive training protocols, the XM-12 will help Piramal Pharma Solutions deliver innovative therapies to more patients, ultimately reducing the burden of disease worldwide. The company’s commitment to quality, safety, and patient-centricity is evident in its strategic investments and partnerships, solidifying its position as a leading CDMO in the pharmaceutical industry.